Market Overview

Morgan Stanley Sees Johnson & Johnson Taking Rx Estimates Higher

Related JNJ
Benzinga's Top Initiations
Guggenheim Securities Initiates Johnson & Johnson At Neutral
U.S., U.K. ISIS Response Differ Widely (Fox Business)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Johnson & Johnson (NYSE: JNJ).

In the report, Morgan Stanley noted, “We're adjusting our pharma estimates modestly to reflect our changing market views and July sales and prescriptions data from IMS. Overall. we're taking our 2016 pharma sales estimates up by 3%, driving a 2% revision in EPS. The largest swing factors include Imbruvica and Invokana.”

Johnson & Johnson closed on Friday at $103.73.

Latest Ratings for JNJ

Oct 2014Guggenheim SecuritiesInitiates Coverage onNeutral
Oct 2014BernsteinDowngradesMarket Perform
Aug 2014JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (JNJ)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters